



► PHARMA POOL

**Susan Benton**  
**Tracey Dawson**  
**SHIRE APPOINTS NEW EXECUTIVE**  
**TEAM LEADS**



Susan Benton

Susan Benton, an industry veteran with more than 25 years of commercial business experience, including 17 years focused in ophthalmology, has been named head of business development, ophthalmics, Shire.

She is responsible for business development initiatives stemming from Shire's organic research and development efforts as well as acquisitions and partnerships.

In 2006, Ms. Benton co-founded Sirion Therapeutics, a fully integrated ophthalmic biopharmaceutical company.

Also joining Shire is Tracey Dawson, a highly experienced healthcare professional with a 17-year track record of sales and marketing success across primary and specialty care medicines.

Ms. Dawson is responsible for developing and leading the overall commercial launch planning process for the ophthalmics business unit. Most recently, she was senior director, global and U.S. marketing at Synageva BioPharma Corp.

► BIOPHARMA POOL

**Rob Bazemore**  
**EPIZYME APPOINTS PRESIDENT AND CEO**



Rob Bazemore

Epizyme, a clinical stage biopharmaceutical research and development company creating novel epigenetic therapeutics for cancer patients, has named Robert Bazemore as president and CEO.

Before joining Epizyme, Mr. Bazemore served as chief operations officer of Synageva through its acquisition in July 2015 by Alexion.

**Dr. Felix Garzon**  
**ACTINIUM PHARMACEUTICALS NAMES**  
**HEAD OF CLINICAL DEVELOPMENT**



Dr. Felix Garzon

Actinium Pharmaceuticals, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, has appointed Felix Garzon, M.D., Ph.D., to the position of senior VP, head of clinical development.

**Dr. Aileen Rubio**  
**SPERO THERAPEUTICS APPOINTS**  
**HEAD OF BIOLOGY**



Dr. Aileen Rubio

Spero Therapeutics LLC, a biopharmaceutical company founded to develop novel therapies for the treatment of bacterial infections, has named Aileen Rubio, Ph.D., as head of biology.

Dr. Rubio joins Spero after spending the last decade in positions of increased responsibility at Cubist.

**Dr. Rene Russo**  
**ARSANIS NAMES CHIEF DEVELOPMENT**  
**OFFICER**



Dr. Rene Russo

Arsanis Inc., a development-stage biopharmaceutical company focused on monoclonal antibody therapeutics for severe infectious diseases, has appointed Rene Russo, Pharm.D., chief development officer. She was

VP, global medical affairs at Cubist Pharmaceuticals, which was acquired by Merck in 2015.

► BIOTECH POOL

**Dr. Deborah Ascheim**  
**CAPRICOR THERAPEUTICS APPOINTS CHIEF**  
**MEDICAL OFFICER**



Dr. Deborah Ascheim

Capricor Therapeutics, a biotechnology company focused on the discovery, development, and commercialization of first-in-class therapeutics, has appointed Deborah Ascheim, M.D., to the position of chief medical officer.

► AGENCY POOL

**Bill McGuckin**  
**Kimberly Wanick**  
**ADVANCED CLINICAL ADDS TO SENIOR TEAM**



Bill McGuckin

Advanced Clinical, a full-service global CRO, functional outsourcing, and strategic staffing solutions provider, has named Bill McGuckin, senior VP, consulting services, to the organization.

Mr. McGuckin brings more than 12 years of consultative sales and



Kimberly Wanick

leadership experience to Advanced. Before joining Advanced, he was VP of life science and technology at a technology solutions provider.

In other company news, Kimberly Wanick, has been named executive director, compliance and quality, to the organization as well as to its leadership team.

**Joe Doyle**  
**HCB HEALTH NAMES VP**  
**OF DIGITAL STRATEGY**



Joe Doyle

HCB Health, an independent healthcare advertising agency, has named Joe Doyle as VP of digital strategy. He is charged with overseeing interactive strategy for both of HCB's offices in Austin and Chicago, and collaborating with his team to develop online solutions including websites, social media campaigns, and online marketing.

**Jim Hall**  
**Mark Kasakevich**  
**James McDermott**  
**Philip Vorhies**  
**CELLO HEALTH MAKES**  
**EXECUTIVE APPOINTMENTS**



Jim Hall

Cello Health BioConsulting has appointed Jim Hall as president. He joins Cello BioConsulting with more than 25 years of experience. Previously, he was a senior partner at Oliver Wyman.

Philip Vorhies has been named VP. He has experience in brand and portfolio strategy, life cycle planning, launch strategy and planning, and forecasting.



Mark Kasakevich

Mark Kasakevich has been named a VP at Cello. He has extensive experience in forming, facilitating and leading cross-functional teams.



Philip Vorhies

Jim McDermott joins Cello as VP. He was a senior member of Campbell Alliance's corporate development practice. <sup>PV</sup>



FOR BONUS CONTENT  
USE YOUR QR CODE READER  
OR GO TO  
[bit.ly/PV1015-Pool](http://bit.ly/PV1015-Pool)



## ► BIOTECH POOL

**Dr. Ronald Peck**  
**KOLLTAN PHARMACEUTICALS APPOINTS**  
**CHIEF MEDICAL OFFICER**

Kolltan Pharmaceuticals, a privately held clinical-stage company focused on the discovery and development of novel, best-in-class antibody-based drugs targeting receptor tyrosine kinases for the treatment of cancer and other diseases, has named Ronald Peck, M.D., as chief medical officer and senior VP, clinical development. Dr. Peck is charged with leading the clinical development of Kolltan's product pipeline.

**Dr. Lukas Scheibler**  
**ACUCELA HIRES EXECUTIVE VP OF**  
**TRANSLATIONAL MEDICINE**

Acucela Inc., a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, has hired Dr. Lukas Scheibler as executive VP of translational medicine.

Dr. Scheibler joins Acucela after a 13-year career in research and development, business development and clinical trial management at Novartis.

## ► BIOPHARMA POOL

**Paul Merrigan**  
**CATALYST PHARMACEUTICALS APPOINTS**  
**CHIEF COMMERCIAL OFFICER**

Catalyst Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, has appointed Paul Merrigan as chief commercial officer. Mr. Merrigan is responsible for leading Catalyst's marketing, sales, and commercial operations.

Before joining Catalyst, Mr. Merrigan served as VP, global marketing, at Aegerion Pharmaceuticals.

**Dr. Brian Murphy**  
**NEMUS BIOSCIENCE APPOINTS CEO**

Nemus Bioscience, a biopharmaceutical company focused on the discovery, development, and commercialization of cannabis-based therapeutics for significant unmet medical needs in global markets has promoted, Dr. Brian S. Murphy to serve as its CEO. Dr. Murphy has served as the CMO of the company since his hiring, a title he will retain, leading all research projects associated with the development of cannabinoid-based therapies for conditions of urgent medical need, including glaucoma and methicillin-resistant staphylococcus aureus (MRSA).

## ► SPECIALTY POOL

**Dr. James Jones**  
**PACIRA PHARMACEUTICALS APPOINTS**  
**SENIOR VP AND CHIEF MEDICAL OFFICER**

Pacira Pharmaceuticals has appointed James Jones, M.D., Pharm.D., to the position of senior VP and chief medical officer. Dr. Jones brings more than 25 years of experience as both a practicing and as an executive at biotechnology and pharmaceutical companies. At Pacira he is primarily responsible for overseeing and guiding the company's clinical research and development efforts for the expanded uses of Exparel. He was most recently VP at The Medicines Company.

**Joseph Oliveto**  
**GALLEON PHARMACEUTICALS NAMES CEO**

Galleon Pharmaceuticals, the first company to build a drug discovery and development platform focusing on pharmaceuticals for sleep apnea and related breathing-control disorders, has named Joseph Oliveto as CEO.

Mr. Oliveto served as president and CEO of Chelsea Therapeutics, a publicly held biopharmaceutical company.

**Scott Plesha**  
**BIODELIVERY SCIENCES STRENGTHENS**  
**SALES FORCE LEADERSHIP**

BioDelivery Sciences International has appointed Scott Plesha as senior VP of sales. In this role, Mr. Plesha is responsible for leading the sales effort for Bunavail, BDSI's maintenance treatment for opioid dependence. Most recently, he held the position of senior VP, GI salesforce and training, for Salix Pharmaceuticals.

**Dr. Jason Slakter**  
**Dr. Irach Taraporewala**  
**OHR PHARMACEUTICAL MAKES EXECUTIVE**  
**APPOINTMENTS**

Ohr Pharmaceutical, an ophthalmology research and development company, has appointed Jason Slakter, M.D., as CEO. He succeeds CEO and founder Dr. Irach Taraporewala, who becomes chief technology officer, and is responsible for the leadership and execution of the company's sustained release drug development programs.

## ► CRO POOL

**Bekki Brown**  
**Dr. Tom Zoda**  
**INC RESEARCH ENHANCES THERAPEUTIC**  
**EXPERTISE WITH KEY PROMOTIONS**

INC Research Holdings, a global Phase I to IV contract research organization, has promoted Bekki

Brown and Tom Zoda, Ph.D., to executive VP, clinical development, general medicine, and executive VP, clinical development, central nervous system.

Ms. Brown, who has been with INC Research since 2001, provides global leadership for the company's general medicine business unit.

Since joining INC Research in 2009, Dr. Zoda has directed and overseen large multi-center global trials focused on psychiatric and neurologic indications in areas such as schizophrenia, Alzheimer's Disease, depression, anxiety, multiple sclerosis and epilepsy.

## ► TECHNOLOGY POOL

**Dr. Denise Basow**  
**David Del Toro**  
**WOLTERS KLUWER MAKES EXECUTIVE**  
**APPOINTMENTS**

Wolters Kluwer has appointed Denise Basow, M.D., as president and CEO of its clinical effectiveness business unit, and David Del Toro as president and CEO of its clinical software solutions business unit. The two new business units were created to drive Wolters Kluwer's key growth initiatives within the healthcare market.

Dr. Basow was previously VP and general manager, clinical decision support. She joined Wolters Kluwer in 2008 as part of its acquisition of UpToDate, where she served as editor-in-chief. Previously, Dr. Basow practiced primary care medicine.


Mr. Del Toro previously served as VP and general manager, clinical documentation. He joined Wolters Kluwer in 2006 and has been in health IT for 30 years.

**Eric Carrasquilla**  
**MODEL N WELCOMES NEW HIRE**

Model N, a provider of cloud-based revenue management solutions to life-science and technology companies, has named Eric Carrasquilla senior VP, product management. In this new role, Mr. Carrasquilla is responsible for leading product strategy, product management and user experience across Model N's suite of applications.

## ► SERVICE POOL

**Dr. Jessica Grossman**  
**MEDICINES360 NAMES CEO**

Medicines360, a global non-profit for women's health with a mission of expanding access to medicines regardless of socioeconomic status, insurance coverage, or geographic location has named Jessica Grossman, M.D., CEO. Before joining Medicines360, Dr. Grossman served as president and founding CEO of Sense4Baby. 

# CMOW CHIEF MEDICAL OFFICER SUMMIT WEST

November 9-10, 2015

Hilton San Francisco Airport Bayfront, Burlingame, California

Led by



Pamela Palmer, MD, PhD  
CMO and Co-Founder  
AcelRX Pharmaceuticals

Lee Allen, MD, PhD  
CMO  
Spectrum Pharmaceuticals

*Driving and maintaining the **appropriate balance** between science, medicine & finance*

**15% off with code PVCE15**

Partial & Full Scholarships Available  
for more information email  
[service@tcflc.org](mailto:service@tcflc.org)

## The R&D Strategic Decision Making Event for Emerging Biotechs

### Benefits of Attending #CMOW2015

Designed by CMOs for CMOs and senior level clinical staff

R&D leadership topics addressing the multifaceted role of the CMO for better decision making

Expanded speaker faculty to support the CMO with the life cycle of the product

Networking and Benchmarking Opportunities



**REGISTER AT [WWW.THECONFERENCEFORUM.ORG](http://WWW.THECONFERENCEFORUM.ORG) OR CALL 646-350-2580**